乳腺导管内癌的个体化治疗研究  

Study of individual in breast ductal carcinoma

作　　者：马刚[1] 陈英男[1] 苏东玮[2] 

机构地区：[1]滕州市中心人民医院普通外科,277500 [2]上海市第二军医大学附属长海医院甲乳科

出　　处：《中国临床实用医学》2010年第7期27-29,共3页China Clinical Practical Medicine

摘　　要：目的根据乳腺导管内癌的临床及病理特点探索其个体化治疗方式及其预后观察。方法根据每例乳腺导管内癌的临床及病理特点采用个体化综合治疗方式，观察其预后。结果本组67例患者根据肿块大小，术中冰冻病理切缘情况，来确定手术方式。其中象限切除术18例，肿块切除活检术10例，乳房单纯切除术16例或加I期乳房假体植入术14例，乳腺肿块切除术＋乳腺癌改良根治术4例，保乳术5例。术后辅助化疗33例，放疗23例，内分泌治疗42例。5年随访，2例死亡。不同术式组五年复发率和生存率无统计学差别。结论导管内癌的治疗主要根据肿瘤大小来决定不同手术方式，同时结合肿瘤组织学特点、性激素受体等因素综合设计个体化治疗。Objective To explore ductal carcinoma in stiu individual treatment, according to clinical and pathological features of breast ductal carcinoma in situ. Methods Analysis of 67 cases of ductal carcinoma in situ in patients with clinical data. Results According to tumor size, intraoperativc frozen pathology to deter- mine the surgical method with 67 patients, Breast quadrant resection 18 cases,Breast tumor resection 10 cases, Breast tumor resection and Modified radical mastectomy 4 cases, Breast conserving surgery 5 cases. Postoperative adjuvant chemotherapy 33 cases, radiotherapy 23 cases, endocrine therapy 42 cases. Adjuvant treatment of patients with Chinese medicine. 5-year follow-up,2 cases died of breast cancer recurrence, other patients were alive. 5-year recurrence rate and 5-year survival rate were not statistically significant between different groups. Conclusion The treatment of ductal carcinoma in situ mainly based on tumor size, to determine the surgical method, combined with histological features hormone receptors to design individual treatment programs.

关 键 词：乳腺 导管内癌 个体化治疗 

分 类 号：R737.9[医药卫生—肿瘤]